financial results
Thermo Fisher Scientific Lowers 2025 Adjusted EPS Guidance in Light of Tariffs, US Policy Changes
Premium
The new guidance reflects the impact from China-related tariffs as well as dampening US grant funding, partially offset by the firm's mitigation actions.
Danaher to Deploy Multiple 'Levers' to Cushion Impact of Tariffs, While China Remains Headwind
Premium
The firm also reported its Life Sciences segment revenues fell 4 percent in the quarter, while Diagnostics revenues decreased 3 percent.
The company said during a conference call following release of its Q1 2025 results that it purchases roughly 80 percent of its supplies from sources within the US.
BioMérieux Confirms Full-Year Growth Guidance as Q1 Sales Rise 14 Percent
First quarter sales in the company's BioFire business increased 21 percent year over year while SpotFire sales nearly tripled.
The firm's CEO said that the US and China will be most affected by the tariffs with an impact of a "few hundred million dollars" in the second half of the year.
Mar 24, 2025
Lucid Diagnostics Q4 Revenues Rise 20 Percent
Mar 4, 2025
Biodesix Q4 Revenues up 39 Percent
Mar 3, 2025
360Dx Top 30 Drops 9 Percent in February
Feb 28, 2025
Castle Biosciences Q4 Revenues up 31 Percent
Feb 26, 2025
Feb 26, 2025